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A B S T R A C T
In the broad field of autoimmunity and clinical immunology, experimental evidence over the past few years have demon-
strated several connections between the immune system and the nervous system, both central and peripheral, leading to
the definition of neuroimmunology and of an immune-brain axis. Indeed, the central nervous system as an immune-priv-
ileged site, thanks to the blood-brain barrier, is no longer a dogma as the barrier may be altered during chronic inflam-
mation with disruptive changes of endothelial cells and tight junctions, largely mediated by adenosine receptors and the
expression of CD39/CD73. The diseases that encompass the neuroimmunology field vary from primary nervous diseases
such as multiple sclerosis to systemic conditions with neuropsychiatric complications, such as systemic lupus erythemato-
sus or vasculitidies. Despite potentially similar clinical manifestations, the pathogenesis of each condition is different, but
the interaction between the ultra-specialized structure that is the nervous system and inflammation mediators are crucial.
Two examples come from anti-dsDNA cross-reacting with anti-N-Methyl-D-Aspartate receptor (NMDAR) antibodies in
neuropsychiatric lupus or the new family of antibody-associated neuronal autoimmune diseases including classic para-
neoplastic syndromes with antibodies directed to intracellular antigens (Hu, Yo, Ri) and autoimmune encephalitis. In the
case of multiple sclerosis, the T cell paradigm is now complicated by the growing evidence of a B cell involvement, par-
ticularly via aquaporin antibodies, and their influence on Th1 and Th17 lineages.
Inspired by a productive AARDA-sponsored colloquium among experts we provide a critical review of the literature
on the pathogenesis of different immune-mediated diseases with neurologic manifestations and we discuss the basic im-
munology of the central nervous system and the interaction between immune cells and the peripheral nervous system.
© 2016 Published by Elsevier Ltd.
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1. Introduction
Autoimmune diseases represent a broad spectrum of systemic con-
ditions which may also manifest with neuropsychiatric manifesta-
tions, while chronic inflammation has been recognized as a crucial
contributor to most major acute and chronic central nervous system
(CNS) disorders and linked to psychiatric disorders such as depres-
sion, anxiety, and bipolar disorder. Further, several immune-mediated
diseases target primarily the CNS, thus increasing the interest in the
field of neuroimmunology and leading to the identification of new
immune-mediated disorders, including anti-neuronal autoimmune en-
cephalitis (AIE) and paraneoplastic neurological syndromes (PNS)
[1].
We herein aim at discussing some of the most recent lines of ev-
idence in neuroimmunology, particularly in the neuropsychiatric in-
volvement of systemic autoimmune diseases and primary CNS im
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mune diseases. While possibly not representing the whole progress in
neuroimmunology that was observed in the past few years, we chose
specific representative issues that appear as the most promising for
the near future with putative implications well beyond the CNS. The
present article is largely based on a colloquium coined “Neuropsychi-
atric Manifestation of Autoimmune Diseases” sponsored by the Amer-
ican Autoimmune Related Diseases Association, held on November
21, 2015 in Washington, DC.
2. The bases of CNS immunology
For decades, the CNS was thought to be an immune-privileged
site, since neurons are separated from the blood vessels by a physical
barrier, the blood-brain barrier (BBB), which exerts both protective
and homeostatic functions [2]. The BBB is composed of tightly con-
nected endothelial cells that form a highly restrictive barrier and cells
are characterized by restricted pinocytosis and transcytosis potential,
and have a peculiar expression of dedicated transporters that regulate
the influx/efflux of nutritive/toxic compounds, a reduced expression
of leukocyte adhesion molecules and the elaboration of specialized
luminal structures involved in tight and adherens junctions that effi-
ciently limit the passive diffusion of blood-borne molecules [3]. The
BBB is surrounded by basement membrane, pericytes and processes
http://dx.doi.org/10.1016/j.jaut.2016.08.005
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of neighboring astrocytes that concur to the neurovascular unit regu-
lating the barrier function, homeostasis and stability [4]. Further, the
BBB is also a key player in maintaining the specialized microenvi-
ronment, and enabling the communication with the systemic compart-
ment; however, it may be altered during inflammatory processes, lead-
ing to both disruptive and non-disruptive changes, with the former ac-
companied histological modifications, such as endothelial cell damage
or tight junction changes, and thus most likely to be harmful. On the
other side, non-disruptive changes occur at the molecular level, and
may provide a mechanism for the communication across a morpholog-
ically intact BBB, and without unselected compromise of the barrier
functions essential to CNS homeostasis. Pro-inflammatory cytokines
may influence BBB function, as receptors for IL-1β, IL-6, and TNF-α
are expressed on the cerebral endothelium [5–7] and systemic IL-1β
and TNF-α cause cerebral endothelial activation, and cyclo-oxygenase
(COX) expression [8].
3. What lies at the bases of neuroimmunopathology
Several mechanisms have been proposed in the pathogenesis of
acute and chronic CNS disorders and these include fascinating models
based on experimental evidence.
First, at a molecular level, adenosine, a nucleoside naturally pro-
duced by neurons and glial cells, is known to modulate CNS func-
tion through a well characterized set of receptors, called P1 purinergic
receptors, and recent studies showed that the axis between adenosine
and adenosine receptor (AR) is an important regulator of BBB per-
meability to macromolecules and cells. Animal studies demonstrated
that extracellular adenosine positively regulates the migration of lym-
phocytes into the brain and spinal cord in a model of autoimmune
encephalomyelitis, while the A2A AR deficient mice, when reconsti-
tuted with wild-type bone marrow cells, develop only very mild signs
of autoimmune encephalomyelitis with virtually no CD4+ T cell in-
filtration in the spinal cord; moreover, in animal models of neurode-
generative diseases, caffeine, a broad spectrum antagonist, inhibits
AR, thus preventing the BBB alteration induced by cholesterol or
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [3,9]. AR al-
ters BBB permeability in vivo and may be recruited by NECA, a
broad spectrum agonist, while both A1 and A2A receptors are stimu-
lated by selective agonists (CCPA and CGS21680) and increase cu-
mulatively and transiently BBB permeability facilitating the entry of
intravenously infused macromolecules (including immunoglobulins
such as the anti-β-amyloid 6E10 antibody) into the CNS [10]. An-
other mechanism to induce the CNS entry of intravenously delivered
macromolecules is the activation of A2A AR, using Lexiscan, an A2A
adenosine receptor agonist [3]. Upon exposure to NECA or Lexiscan,
murine brain endothelial cells lower their transendothelial electrical
resistance, increasing paracellular space and permeability, and further-
more increase the formation of actinomyosin stress fiber, indicating
that ARs signaling initiates cytoskeletal organization and cell shape
changes, in a reversible manner. Within tight junctions, A1 and A2A
receptor agonist signaling alters protein expression, i.e. claudin-5 and
ZO-1, particularly in cultured brain endothelial cells [10–12]. In hu-
man brain endothelial cells, recent studies confirmed that agonist-in-
duced A2A receptor signaling transiently permeabilizes the cell mono-
layer allowing the passage of both drugs and Jurkat human T cells in
vitro in a paracellular type, suggesting that also in humans brain cells
respond to adenosine in vitro. Thus, by regulating the expression level
of factors crucially involved in tight junction integrity/function, sig-
naling induced through receptors for adenosine acts as a potent, en-
dogenous modulator of BBB permeability in mouse models as well as
in human cellular models in vitro.
Second, at a cellular level, the expression of CD39/CD73 is a reg-
ulator of tissue barrier function, trough the control of ATP levels [13].
In the BBB, CD73 expression is under a low steady state but sensitive
to cAMP and HIF1 through its promoter [14], and can regulate home-
ostasis by preventing high ATP concentrations, and generating adeno-
sine instead, which contribute to an anti-thrombotic microenvironment
[15]. The CD39/CD73 axis regulates also the leukocyte migration in-
duced by chemokines and immune cell adhesion to the endothelium,
amplified by high ATP levels and limited by adenosine levels [16–19].
Overall, all mechanisms underlying the BBB alterations is not well un-
derstood, however, AR signaling is crucial in controlling BBB perme-
ability and it could be used for a precise time-dependent control, with
some reagents targeting ARs that could be used to block the entrance
in the CNS of inflammatory cells thus preventing the irreversible dam-
age seen in neuro-inflammatory disorders.
Regardless of the primum movens, when inflammatory cells and
cytokines are released in the CNS, the microglia, endothelia, astro-
cytes, ependymal cells and meningeal cells lead to innate immunity
activation. In particular, microglial cells upregulate major histocom-
patibility complex (HLA) and costimolatory molecules, moreover re-
leasing cytokines and chemokines that recruit monocytes, lympho-
cytes and dendritic cells. Microglial cells are crucial for generating
and maintaining the inflammatory milieu, while dendritic cells play
a role in antigen presentation to invading T cells [20,21]. In parallel
with leukocyte entry, neural antigens are accessible to the periphery,
as demonstrated in infections, and thus the adaptive immune response
is initiated with antigen specific T cells, which, guided by chemoat-
tractants, cross the BBB and infiltrate the CNS, with CD4+ T cells
mainly found in the perivascular cuffs and meninges, while CD8+ also
in the parenchyma. When T cells encounter their antigen, CD4+ recruit
macrophages, leading to the release of proinflammatory cytokines and
toxic molecules (i.e. nitric oxide, IL1, IL6 and TNF), while CD8+ cells
might attack also oligodendrocytes and neurons [22]. Furthermore, B
cells are involved in the CNS inflammation, and release soluble im-
munoglobulins directed to membrane bound or soluble antigens [23].
The complex interaction between the CNS and the periphery lead
to the discovery of functional meningeal lymphatic vessels, that are
crucial to the development of the adaptive immune response. Intrigu-
ingly, it has been demonstrated that CNS-derived antigens induce an
immune response in the deep cervical lymph nodes and that the CNS
functional lymphatic system within the meninges that drains cellular
and soluble constituents from the CSF into the deep cervical lymph
nodes [24–27]. Meningeal lymphatic vessels enable fluids, macromol-
ecules and immune cells to drain from the CNS to the deep cervical
lymph nodes, and with new techniques, it has been demonstrated that
lymphatic endothelial cells expressing conventional hallmarks line the
dural sinuses and exit the CNS at the base of the skull, with scattered
lymphatic valves [26,27]. Meningeal lymphatic vessels may be the
route for meningeal antigen presenting cells (APC) and soluble fac-
tors from the brain to reach deep cervical lymph nodes, in addition to
the previously described routes [26,27]. This APC trafficking could
be responsible for the generation of self-reactive T cells. Moreover,
CNS lymphatic vessels may be equipped with a unique molecular ar-
mamentarium to maintain T cells anergy, and failure of such mecha-
nism may potentially underlie the etiology of brain autoimmunity, as
in multiple sclerosis (MS). Finally, macromolecules and protein ag-
gregates released from the CNS may be removed by the lymphatic
system with a system becoming less efficient with aging and result-
ing in the deposition of protein aggregates, as observed in Alzheimer's
diseases [28].
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4. Neuropsychiatric involvement is SLE
SLE is the prototype of systemic autoimmune diseases, with
chronic, relapsing-remitting clinical manifestations, which may affect
the CNS, beside more classically involved organs [29,30]. Neurologic
involvement is coined neuropsychiatric-SLE (NPSLE) and may be a
frequent and early manifestation, reported in a variable proportion of
patients (12–95%), with an enormous impact on the quality of life and
associated with a poor prognosis [31–34]. In fact, neurological symp-
toms and signs are included in the American College of Rheumatol-
ogy (ACR) classification criteria for SLE [35] and may include also
neuropsychiatric manifestations such as cognitive changes, mood and
anxiety disorders, confusional state, and psychosis. NPSLE has been
reported to be more frequent in women with a peak incidence at child-
bearing age, thus suggesting a hormonal dysfunction that might pro-
mote the disease development and progression in susceptible individ-
uals [36]. Moreover, non-white individuals have a higher risk of de-
veloping SLE and NPSLE, suggesting a genetic predisposition [37].
Clinical manifestation of NPSLE vary widely, with the most com-
mon being cognitive dysfunction, in up to 80% of patients, mood and
anxiety disorders in 57%, headache in 72%, seizure and stroke, espe-
cially in presence of anti-phospholipid antibodies. Uncommon mani-
festations (<5%) include acute confusion, psychosis, and myelopathy,
while rarely (<1%) aseptic meningitis, movement disorders and lupus
demyelination have been observed [38]. Cognitive dysfunction is the
most common NPSLE manifestation when mild-to-moderate, while
the severe form develops only in 3–4% of patients [39]. The most
common domains affected are the verbal and visual memory, attention
and psychomotor speed [40]. Depression is the predominant psychi-
atric manifestation of NPSLE, with rates as high as 54% of patient,
and might be associated with autoimmune CNS lesions [41]. Over-
all NPSLE is a complex entity, with partially unknown pathogenesis
and almost no biomarker, thus the management and treatment might
be challenging. Recently, recommendations for the management of
NPSLE were published by the European League Against Rheumatism
(EULAR) [39].
The pathogenesis of NPSLE has not been fully elucidated as ge-
netic factors have been intensively investigated, and recently the TR-
PC6 rs7925662 polymorphism was recognized in NPSLE [42], while
other studies identified mutations in TREX1, encoding for three-prime
repair exonuclease 1 (also known as DNase III) in NPSLE, while
TREX1 polymorphisms are associated specifically with seizures in
SLE [43,44]. However, serum autoantibodies, particularly anti-ds-
DNA, are believed to play a key role in the development of NPSLE
as anti-dsDNA may cross-react with anti-N-Methyl-D-Aspartate re-
ceptor (NMDAR) antibodies. These latter antibodies recognize an ex-
tracellular conformation-dependent epitope close to the amino acid
369 of the GlyN1 of the NMDAR, and reduce receptor density on
the neuronal surface resulting in neuronal dysfunction, in a reversible
manner [1]. Anti-NMDAR antibodies are highly specific for anti-
NMDAR encephalitis, but have been reported in up to 49% of SLE
cases. Whether this cross-mimicry mechanism may be responsible
for the NPSLE remains unclear as antibody-mediated brain lesions
require the permeability of the BBB, which may be altered by en-
dothelial dysfunction, due to a pro-inflammatory response; anti-NM-
DAR/dsDNA antibodies have been reported to be able to enter the
brain tissue after altering the BBB and cause neuron damage, lead-
ing to memory alterations and stress response in mice. Interestingly,
animal studies showed that anti-NMDAR/dsDNA antibodies may af-
fect also the offspring of mothers with SLE while in the
uterus, due to the lack of BBB, causing cell death and abnormalities
in the fetal neocortex. Epidemiological studies support this hypothesis
as children of SLE mothers have higher frequency of cognitive defects
compared to controls. In animal studies, anti-NMDAR/dsDNA anti-
bodies were reported to increase the female fetus loss, due to enhanced
GluN2A expression in the brain stem of female fetuses. In this view,
decoy antigens may represent a therapeutic strategy.
Anti-ribosomal P protein antibodies have been reported at high
titers in patients with NPSLE, however the association with specific
disease manifestations remains debated, particularly at differentiating
phenotypes such as psychosis, mood disorders, and other diffuse or fo-
cal manifestations [41]. Nonetheless, experimental evidence showed
that anti-ribosomal P protein antibodies recognize neurons within the
hippocampus, cingulate and primary olfactory piriform cortex and in-
duce a long-term increase in depressive like behavior [45]. Finally,
these antibodies may exert a direct neuropathogenic potential, by in-
ducing a rapid and sustained increase in calcium influx and subsequent
apoptosis in rat neurons that express a cell-surface protein termed
p331, that was designated as the new neuronal surface P-antigen [46].
Additional serum autoantibodies have been associated with
NPSLE, including anti-MAP-2 antibodies, which are directed towards
a cellular protein essential for cytoskeletal integrity and specific to
neurons. Recent evidence shows that antibodies directed towards poly
(ADP-ribose) polymerase 1 (PARP-1) are less frequent in NPSLE
compared to other SLE phenotypes with no kidney injury or neuropsy-
chiatric symptoms [41]. Serum PARP-1 antibodies influence the re-
pair of single-stranded DNA breaks, suggesting a potential role in
NPSLE pathogenesis [41].
Serum anti-phospholipid (aPL) antibodies are commonly detected
in SLE, and might cause focal neurological symptoms after vascular
events [47]. The aPL family targets are anionic phospholipids which
can be detected in plasma membranes and regulate the blood clotting
cascade, favoring the activation of procoagulants, promoting throm-
bosis [48]. In this view, anti-phospholipid antibodies, especially lupus
anticoagulant and anti- β2 glycoprotein 1 antibodies, may act as direct
contributors to the development of thrombosis and focal neurological
manifestations. APL antibodies, especially and anti-β2 glycoprotein-1,
have been associated with the following NPSLE manifestations: in-
tractable headaches, ischemic stroke and seizures, notably, being the
most predictive antibodies for all of these manifestations [49].
5. Antibody-associated autoimmune disorders
Antibody-associated neuronal autoimmune diseases constitute a
newly recognized heterogeneous group of syndromes that result from
an autoimmune reaction to neural antigens, mainly divided in two
groups: classic paraneoplastic syndromes (PNS) with antibodies di-
rected to intracellular antigens (Hu, Yo, Ri) and autoimmune en-
cephalitis (AIE). PNS occur in patients with active cancer, and are
characterized by non pathogenic serum autoantibodies. Conversely,
AIE-associated autoantibodies are directed towards easy accessible
antigens, such as synaptic receptors and membrane antigens, caus-
ing direct neuronal injury [1]. AIE are associated with different an-
tibodies directed mainly towards synaptic receptors, including NM-
DAR, the α-amino-3-hydroxy-5-methyl-4-isoxazol-propionic acid re-
ceptor (AMPAR) or the γ-amino-butyric acid B-receptor (GABAbR)
[50–52]. Several patients with AIE have autoimmune comorbidities,
including systemic diseases and positivity for other serum autoan-
tibodies, such as antinuclear antibodies (ANA), and
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anti-thyroid peroxidase antibodies [53] undetectable in the CSF. Most
data on AIE pathogenesis were gathered from NMDAR-antibodies
found in NMDAR-encephalitis. NMDAR antibodies, as discussed
previously, bind to an extracellular conformational epitope region
close to the amino acid 369 of the GluN1 NMDAR subunit and re-
duce the receptor density causing a reversible direct neuronal dysfunc-
tion [54,55]. Other autoantibodies may act through different mecha-
nisms, as GABAbR-antibodies influence receptor function relocating
the receptor to extrasynaptic sites [1], while AMPAR antibodies re-
duce the receptor density at synaptic and extrasynaptic sites, along
with a reduction of the AMPAR-mediated miniature excitatory post-
synaptic currents [53].
The triggers that stimulate the development of synaptic autoim-
munity remains unknown, but infections from herpes simplex virus
(HSV) have been proposed, since 20% of patients with HSV en-
cephalitis (HSVE) have relapsing symptoms, especially in children,
without viral reactivation, new necrotic lesions, or response to acy-
clovir. Most patients develop a chorea characterized by dystonia or
ballismum, agitation, sleep dysfunction and seizures [53]. These pa-
tients in some cases develop anti-NMDAR antibodies, suggesting
anti-NMDAR encephalitis as a complication responding to im-
munotherapy [53].
The crucial issue in the diagnostic workup is the identification
of serum autoantibodies, and different techniques are available: tis-
sue-based assay, call-based assay, primary cultures of neurons and
immunoprecipitation. Currently, most laboratories use cell-based as-
says for the diagnosis of AIE, as a highly sensitive and specific assay.
Since new autoantibodies may not be identified, tissue-based assays
are a good screening method, detecting most of the known antibod-
ies, while immunoprecipitation is used in research settings [1]. Serum
autoantibodies are usually tested on the CSF, and are usually always
present, while the serum might be negative in 14% of cases, or even
show false positive results. Antibody titers may also be determined but
their relationship with disease activity and outcome has been investi-
gated only in the context of anti-NMDAR-encephalitis [54]. From a
clinical standpoint, AIE manifests with different symptoms, anti-NM-
DAR encephalitis develops as a multistage process, starting from ag-
itation, memory deficits, and then progressing to coma, hypoventila-
tions and autonomic instability. Patients may experience a prodromic
syndrome and in a few days develop progressive anxiety, agitation,
psychosis, memory deficits and speech reduction. Encephalitis associ-
ated with other antibodies, such as LG1, GABA(B)R and AMPAR, are
described as classic limbic diseases, but some additional feature may
suggest the target antigen: LG1 is usually associated with hypona-
tremia, GABA(B)R with seizures and up to 50% of cases with small
cell lung cancer; some autoantibodies may cause also systemic symp-
toms, such as diarrhea or gastrointestinal dysfunction in DPPX-anti-
bodies [1,53].
Recently, autoimmunity has been linked to neurodegeneration,
with the characterization of IgLON5-antibody in patients with sleep
dysfunctions, abnormal behavior, movements and brainstem symp-
toms with a chronic progressive disease course. In some patients tau
protein aggregation in the hypothalamus, thalamus and brainstem has
been observed but it remains unclear whether antibodies have a path-
ogenic potential or represent an epiphenomenon [56]. The treatment
is based on immunomodulators and anti-NMDAR encephalitis usually
resolves rapidly after treatment.
6. Multiple sclerosis
Multiple sclerosis (MS) is a chronic disease characterized by a va-
riety of neurological signs and symptoms disseminated in time and
space, ultimately causing disability in the white population [57]. MS
affects almost 2.1 million people worldwide, and approximately
250,000–400,000 only in the United States [58]. Women are predom-
inantly affected, as for most autoimmune diseases but the etiology re-
mains largely unknown, with genes and environmental factors concur-
ring to the disease onset [59]. The MS concordance is 30% in monozy-
gotic twins and 3% in siblings of patients with MS, suggesting an im-
portant role of genes in the development of the disease, and lately
the HLA-DR1501 and HLA-DQ0601 alleles, alleles, which encode re-
striction elements of T cells, are associated with an increased risk of
developing MS [60].
The pathogenic mechanisms underlying MS have not been eluci-
dated, also reflecting the different phases and the variability in the
evolution of the disease [61,62]. In the early phases, microglia and
macrophages activate, but the BBB remains intact with limited in-
flammatory infiltrate seen in the brain, with virtually no demyelina-
tion and astro-gliosis. Later in the disease progression, between 6 and
20 weeks, lesions illustrate the most active phase of the disease, and
the inflammatory infiltrate begins to appear in lesions, the BBB starts
leaking, and there is evidence of demyelination and reactive astro-
cytes, along with proliferating oligo-dendroglial cells at the lesion bor-
ders. Numerous cytokines and chemokines are released into the lesion,
including Th1 and Th2 cytokines. After 20 weeks, the number of in-
flammatory cells decreases and remyelination occurs even if incom-
plete [63–65].
For decades, MS has been considered a T cell mediated disease,
as myelin-protein-specific T cells can be retrieved from the blood or
CSF of patients, with the involvement of plasmacytoid dendritic cells
[66]. Both CD4+ and CD8+ T cells are present in MS lesions, with
CD4+ T cells being found predominantly in the perivascular cuff, and
CD8+ T cells being more prevalent in the center and border zone of
the lesion [22]. Myelin-protein-specific T cells may be found in blood
or CSF of MS patients, but are highly aspecific, being found also in
healthy controls [67]. The importance of B cells is represented by the
presence of autoantibodies in patient sera but have been neglected for
years. Autoantibodies are present also in the CSF, as demonstrated by
the presence of oligoclonal bands or intrathecal IgG production, which
remain still the only diagnostic laboratory marker for MS. Recently,
dominant B-cell clonotypes, containing replacement mutations in their
B-cell-receptor genes, have been identified in CSF and lesions of MS
patients, suggesting an antigen-driven selection process; moreover,
immunoglobulins (predominantly IgG1) are released into the CSF and
lesions of MS patients, while plasmablasts and plasmacells can be
identified in the CSF of MS patients, and B-cell cytokines, such as tu-
mor-necrosis factor ligand superfamily member 13B (BAFF), are also
detected in MS lesions. Although these findings strongly support a
role for the humoral immune response in MS, the specificity and func-
tion of this response remains to be determined. A serum antibody that
binds aquaporin has recently been described in approximately 50% of
patients with MS-related neuromyelitis optica, suggesting that might
prove helpful as an early diagnostic biomarker [22]. Moreover, B cells
have been reported to influence Th1 and Th17 cells, central lympho-
cyte lineages in MS. In humans, in vitro B cell depletion in MS re-
duces Th17 cells after polyclonal stimulation [68], and patients with
MS undergoing B cell depletion therapies have lower levels of IL-17
production in vitro [69]. Further, recent studies show that B cells from
MS patients are capable of directly supporting neuro-antigen-specific
Th17 responses [70].
MS pathogenesis has been investigated also at molecular levels
and data support the involvement of the purinergic system signaling,
with adenosine, which can control the immune system and inflam
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mation, and adenosine receptors that may be considered as novel po-
tent therapeutic targets in MS [71]. It is suggested that adenosine and
the AR are involved in modulation of neuroinflammation in MS and
experimental models. The reported dysfunction of the CNS AR shows
that signaling of this receptor contributes to MS development in pa-
tients and in animal models, with a bidirectional effect in neuroinflam-
mation and brain injury. The expression of A1R in macrophages in
both the brain and blood cells is reduced in MS, which proposes its
role in macrophage activation and the CNS inflammation, moreover
A1R regulates severity of the disease in animal models, especially in
relation with neurobehavioral and neuropathological outcomes, such
as demyelination and axonal damage. On the other hand, A1R acti-
vation reduces the CNS inflammatory response, regulating TNFalpha
and IL- 6 levels; however, A1R activation reduces IL-6 production in
MS, while in healthy controls A1R inhibits TNFalpha levels [72–74].
In patients with MS, magnetic resonance imaging (MRI) studies
showed that axonal damage and loss ultimately determine the neu-
rologic disability. Axonal damage occurs in the early stages of the
disease: CD8+ T cells directly target neurons, while CD4+ response
recruit macrophages, leading to the release of inflammatory media-
tors and toxic molecules, binding of autoantibodies to neuronal sur-
face antigens, followed by complement activation or antibody medi-
ated phagocytosis of axons [22].
Treatment of MS has significantly evolved in the last years;
nonetheless, the disease may still lead to chronic disability and a poor
quality of life. Currently, first line treatments include immunomod-
ulating agents, such as interferon-beta, glatiramer acetate (GA), ter-
iflunomide, and dimethyl fumarate [75]. Interferon beta is a natu-
rally occurring polypeptide predominantly produced by fibroblasts, its
anti-inflammatory effects are the result of the inhibition of T-lym-
phocyte proliferation, a shift of cytokine response from an inflam-
matory response to an anti-inflammatory profile, and reduced migra-
tion of inflammatory cells across the BBB [76]. GA is a synthetic
polypeptide composed of the most prevalent amino acids in myelin
basic protein modulates autoreactive T cells, inhibit monocyte activ-
ity and induce bystander immune suppression at lesion sites [22,77].
Teriflunomide is an immunomodulatory agent that selectively and re-
versibly inhibits the mitochondrial enzyme dihydroorotate dehydro-
genase, required for de novo pyrimidine synthesis, reducing cell pro-
liferation, its therapeutic effect in MS is not fully understood but it
is probably mediated by a reduced number of circulating lympho-
cytes [78]. Dimethyl fumarate is an immunomodulatory agent with
anti-inflammatory properties, but the mechanism of action in MS is
only partially understood, its activity is primarily mediated through
activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
transcriptional pathway, but it is has also been shown to upregu-
late Nrf2-dependent antioxidant genes [79]. More recently, new treat-
ments approved for MS therapy are natalizumab, alemtuzumab, and
fingolimod, showing important beneficial effects for patients with re-
lapsing-remitting MS. Natalizumab was the first monoclonal anti-
body approved for MS therapy, it is directed against α4-integrin, and
blocks the interaction with its ligands. The mechanism of action is
largely through preventing adherence of activated leucocytes to in-
flamed endothelium, thus inhibiting the migration of inflammatory
cells into the CNS [80]. Fingolimod is an oral sphingosine 1-phos-
phate receptor (S1PR) modulator that subsequent to its phosphory-
lation binds with high affinity to S1PR, which in turn leads to an
internalization and degradation of the receptor in different tissues
and cell types, including lymphocytes. As a consequence, fingolimod
inhibits the ability of autoreactive lymphocytes to egress from the
lymph nodes towards the CNS [81]. Finally, B cell depletion demon
strated impressive and sometimes surprising results with alem-
tuzumab, a recombinant, humanized monoclonal antibody directed
against CD52, a cell surface antigen present at high levels on espe-
cially T and B cells. Alemtuzumab acts through antibody-dependent
cellular cytolysis and complement-mediated lysis following cell sur-
face binding. The mechanism by which alemtuzumab exerts its thera-
peutic effects in MS is suggested to be by a depletion and repopulation
of lymphocytes that reduces the potential for relapses and thereby de-
lays disease progression [82]. Other B cells depleting therapies have
been used in MS: antiCD20, such as rituximab, ocrelizumab, and ofa-
tumumab were effective in MS, rituximab trials were terminated in fa-
vor of newer molecules with better biological properties and reduced
immunogenicity [83].
7. Autoimmunity in psychiatric disorders
Psychosis is a severe mental condition where thoughts or behaviors
are disconnected from reality, manifesting with hallucinations (per-
ceptions in the absence of a stimulus), delusions (fixed false beliefs),
and irrational behavior. Schizophrenia is the disease with the highest
prevalence of psychosis, followed by bipolar affective disorder. Schiz-
ophrenia is associated with a dramatic reduction in the quality of life,
and life expectancy, due to multiple medical comorbidities [84]. The
pathogenesis of psychosis is multifactorial and in the last decade a
neurodegenerative hypothesis has been prevailing, with initial studies
demonstrating broad pathological changes in the brain parenchyma,
such as ventricular enlargement, decreased gray and white matter
volumes, decreased overall brain volume and cognitive decline [85].
However, more recently the etiology of psychosis has been linked to
a “disconnection syndrome”, where incoming neural activity is poorly
integrated across wide regions of the brain [86]. The immune sys-
tem has also been extensively investigated, suggesting that an in-
flammatory autoimmune process may be present in some patients,
as supported by the detection of specific autoantibodies against neu-
ronal antigens linking the dysfunction paradigm with immune-medi-
ated mechanisms [85]. Moreover, several immune dysfunctions have
been identified in schizophrenia: variants of immune system genes
have been identified in genome-wide association studies and these
may share a common genetic risk factor that give rise to psychotic
disease and autoimmune syndromes. Several cytokines have been
identified as disease markers, particularly IL-1β, IL-6, and TGF-β,
while IL-12, IFN-γ, TNF-α, and sIL-2R, being overexpressed, in-
dependently of psychotic episodes or treatment. The gastrointestinal
tract may play a role in triggering autoimmunity and represent the
connection between the mental disorder and autoimmune manifes-
tations, and celiac disease is more prevalent in patients with psy-
chiatric disorders and schizophrenia, as reported as early as in the
1950s. Celiac disease and schizophrenia share a genetic predisposi-
tion, as a susceptibility locus for schizophrenia was identified in the
6p21 region, which also houses the MHC loci and its resident hu-
man leukocyte antigen (HLA) genes, of which the HLA-DQ2 het-
erodimer or DQ8 haplotype are specific for celiac disease [87]. More-
over, IgA antigliadin antibodies (AGA) (indicative of gluten-sensi-
tivity) and tissue transglutaminase antibodies (tTG) (suggestive of
celiac disease) are present in 23% and 5% of patients with schiz-
ophrenia, respectively, compared to 3% and 1% of controls [88].
Well representing the dichotomy between celiac disease and gluten
sensitivity [89], schizophrenic patients testing positive for AGA and
with associated gluten sensitivity may represent a subgroup of people
with schizophrenia who have a different etiology or manifestation of
schizophrenia related to the chronic inflammatory state. The most re-
cent studies agree that schizophrenia is associated with gluten sensi
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tivity, rather than celiac disease, in a subgroup of patients [90]. Fur-
thermore, AGA might have a pathogenetic role in the development
of neuropsychiatric comorbidities, as suggested by animal models
in which the injection of sera from patients with celiac disease but
no neurologic symptom leads to equilibrium alterations, due to a
cross-reactivity between Purkinje cell epitopes and gluten peptides.
Moreover, gliadin can activate the cytokine production in monocytes
and macrophages [91]. In vitro studies show that murine peritoneal
macrophages treated with different concentrations of gliadin induce
pro-inflammatory genes, including TNF-α, IL-12, IL-15, IFN-β iNOS,
IP-10, and MCP-5, indicating that gliadin and its active peptides are
capable of increasing expression of a repertoire of inflammatory genes
[92]. In schizophrenia, the lymphocyte response to gluten subfractions
is similar to celiac disease [93] and it has been hypothesized that celiac
disease and gluten sensitivity may trigger psychiatric and neurologic
symptoms in genetically susceptible individuals. Asymptomatic pa-
tients may have white matter hyperintensities in frontal and occipi-
toparietal cortices and gray matter reduction in the cortex and caudate
nucleus, and patients who are not on a gluten-free diet demonstrate
IgA antibodies to brain blood vessels. Gluten ataxia is a well rec-
ognized neurologic complication related with celiac disease. Gluten
ataxia is characterized by positive AGA, changes in the cerebellum,
and ataxic symptoms including upper or lower limb ataxia, gait ataxia,
and dysarthria [94]. In addition to AGA, patients with gluten ataxia
have oligoclonal bands in their cerebrospinal fluid, inflammation at
the cerebellum, and anti-Purkinje cell antibodies. The sera of patients
with ataxia express high reactivity with cytoplasmic proteins of neu-
rons in vitro studies, suggesting a difference in neurological effects
of sera from celiac disease patients with no neuropathy and patients
with gluten ataxia and neuropathy [95]. Epilepsy is another neurologic
manifestation of gluten sensitivity or celiac disease.
Gluten-free diet is the only effective treatment for celiac disease
and gluten sensitivity but few studies have investigated the role of
diet in the management of schizophrenia, with unconclusive results.
Nonetheless, in patients with antibodies to anti-tTG or AGA a gluten
free diet may lead to a schizophrenia improvement as well as robust
amelioration of the extrapyramidal dysfunction [96].
8. Immune mediated and virus associated encephalomyelitis
Encephalomyelitis represents an inflammatory condition of the
brain and spinal cord resulting from the immune response to a vi-
ral infection. Indeed, viral encephalomyelitis is an important cause of
morbidity and mortality worldwide and numerous encephalitic viruses
are emerging and re-emerging due to changes in virulence, spread to
new geographic regions, and adaptation to new hosts and vectors [97].
Viruses that cause more frequently encephalomyelitis include her-
persviruses, RNA viruses, enterovirus, rhabdovirus, alphavirus, fla-
vivirus, and bunyavirus, while paramyxoviruses and arenaviruses can
cause acute encephalitis [98,99]. Despite the large number of viruses
known to cause neurologic injury, in most cases the etiologic agent
cannot be identified. The infection generally begins outside the CNS,
and the immune system prevents the virus entry in the CNS; viruses
may then enter the CNS as a consequence of viremia or dissem-
ination from a neighboring organ, such as the nasal olfactory ep-
ithelium. In physiological conditions, the BBB inhibits the access
to neurons while, when ineffective, the virus may attack neurons.
Nevertheless, some viruses (HSV, varicella zoster and rabies) use
a specialized CNS entry pathway, as they can enter the nerve ter-
minal in peripheral organs, and then use neural transport mecha-
nisms to transport the virions to the neuron cell body where
replication occurs [100,101]. During encephalitis, the virus attacks
neurons, while more rarely it may attack the endothelial cells causing
vascular complications, or the glial cells causing demyelination, en-
cephalopathy or dementia. Some viruses cause widespread infections
of the CNS, while other, such has HSV type I affects the hippocampus,
causing behavioral alteration. The neuronal damage can be caused di-
rectly by the virus, trough inducing cell apoptosis or necrosis, or by the
immune response against the infection [102–104]. The inflammatory
response directed towards the infected neurons is the major contrib-
utor to the clinical phenotype. As a consequence, the astrocytes and
microglial cells become activated and proliferate, monocytes and lym-
phocytes infiltrate the perivascular space and the parenchyma, neu-
rotoxins, reactive oxygen species are produced, and there in an in-
crease of glutamate and pro-inflammatory cytokines production. The
acute process may be fatal, but is crucial for recovery and virus clear-
ance via type I IFN which is essential for the early control of virus
replication, and both humoral and cellular arms of the adaptive im-
mune response play important roles in clearance, as mice deficient in
all components of adaptive immunity develop persistent nonfatal in-
fection. Virus clearance from infected cells in the brain parenchyma
and recovery from infection is a multistep process: first, the virus
spread to new cells is inhibited, then clearance of cell-free infectious
virus [105]. Subsequently, virus-infected cells must be eliminated or
intra-cellular virus replication must be permanently suppressed [105].
The immune system eliminates infected cells and the process, due to
the peculiar structure of neurons, leads to permanent damage. The
elimination of infected cells may occur by virus induced or immune
mediated cytolysis, and T cells are crucial mediators as mature neu-
rons are relatively resistant to cell death: CD4+ and CD8+ T cells ex-
hibit their cytotoxic properties and kill the neurons [106]. Non-cy-
tolytic mechanisms are also enabled to control the infection, and in
alphavirus encephalitis IFN gamma and anti-viral antibodies are pro-
duced, IFN gamma activates the Jak/STAT signaling pathway to block
viral replication in motor neurons without toxicity, antibodies are pro-
duced against the E2 viral glycoprotein which is expressed on the
cell surface of infected neurons [107–109]. This process does not
completely eliminate the viral RNA from neurons, also when the en-
cephalitis is recovered. Long-term immunologic tolerance is required
to prevent virus reactivation or the development of a chronic disease,
and humoral immunity is thought to play a role with antibodies, which
however need either to be produced in the CNS by long-lived resident
antibody secreting cells or enter the BBB [110]. The long-term con-
trol is not always successful, leading to chronic or recurrent neurologic
disease in a subgroup of patients.
9. Neural-immune system interaction in the periphery
The nervous system has been recently recognized as an important
partner of the immune system in regulating inflammation, and neu-
ronal pathways are physiological mediators of the immune function.
Moreover, neuronal function is altered when the immune system is
deregulated and in presence of inflammation. Neurons and immune
cells interact with each other, especially within innate immune func-
tion and animal studies suggest that the two systems share their phy-
logenetic origin, and neurons are necessary for the innate immune re-
sponse. In the periphery, neurogenic inflammation has been identi-
fied, and specialized (nociceptor) neurons may detect cytokines and
other inflammatory products released by activated cells and mediate
inflammatory pain [111,112]. Moreover, neuron release substance P
with proinflammatory activities first linked to enhanced production of
IL-1, TNF-α, and IL-6 by monocytes, causing vasodilation, and act as
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immune cells attractants and activators. Conversely, animal studies in-
dicate that substance P and signaling through the neurokinin-1 recep-
tor on myeloid cells leads to enhanced type 1 immunity by promot-
ing the production of IL-12 and IL-23 [113]. Adaptive immunity is
also regulated within this axis, and T cells interact with neuropep-
tides with sympathetic neurons negatively regulating dendritic cells
(DC)-dependent priming of CD8+ T cells during a primary viral infec-
tion. Moreover, the sympathetic activity negatively regulate type 1 re-
sponses via norepinephrine production by reducing IL-12 production
by DCs and by acting directly on T cells which express the β2-adren-
ergic receptor [113]. These functions cumulatively have protective ef-
fects against infections, but in the context of chronic inflammation
may play a role in the development of autoimmunity. In the neuro-im-
mune axis, the CNS communicates with the periphery trough different
pathways: i.e. infiltration of immune cells in the brain, vagus neurons
transmission to the nucleus tractus solitarius. Efferent vagus signaling
has also been demonstrated to reduce the excessive release of TNF and
other pro-inflammatory cytokines, and has been named the “choliner-
gic anti-inflammatory pathway”, which is mediated by the alpha7ni-
cotinic acetylcholine receptor [114]. These findings lead to the defini-
tion of a new immunoregulatory mechanism, the inflammatory reflex,
in which the vagus nerve fibers communicate with the immune system
to control an excessive pro-inflammatory signaling. Splenic nerves are
involved in the control of inflammation, as a subset of splenic T cells
containing functional choline acetyltransferase are crucial mediators
of the inflammatory reflex. The neurons influence DC migration and
motility, and DC have been located in close proximity to sensory neu-
rons in skin, lung, and gut. Moreover, immature DC are responsive to
both norepinephrine and neuropeptides [113]. Motility might also be
affected, as sensory nerves produce CXCL12 and VEGF-A, which are
required for arteriogenesis and vascular branching.
In autoimmune diseases, chronic inflammation favors an inflam-
matory neuronal configuration characterized by local neuronal imbal-
ance (favoring sensory over sympathetic nerve fibers) and increased
systemic sympathetic nerve activity, with the consequence of empty-
ing energy stores and supporting tissue inflammation and destruction
[115]. Animal models of inflammatory arthritis show that the sympa-
thetic nervous system may exert both anti-inflammatory and pro-in-
flammatory properties, depending on the site of its interaction with im-
mune cells [116,117]. Adaptive immunity contributes to the dual ef-
fects of the sympathetic nervous system, as it has been demonstrated
that activated B-cells decrease inflammation upon β-adrenergic stim-
ulation [118]. However at this stage of disease, the density of sym-
pathetic nerve fibers is reduced in inflamed tissue, and the signaling
through the β-adrenergic receptor might be disturbed [119].
In patients with rheumatoid arthritis, a loss of sympathetic nerve
fibers and/or maintenance or increase in sensory nerve fibers has been
documented, moreover also other chronic inflammatory conditions
have been demonstrated to have similar findings [120–122]. Chronic
inflammation has also been associated with an increase in systemic
sympathetic activity and might be linked to increased cardiovascular
risk [123]. In contrast to the increased activity of the sympathetic ner-
vous system, activity of the parasympathetic nervous system appears
to be reduced in chronic inflammation.
10. Concluding remarks
The road to understanding the mechanisms of neuroimmunology
is fascinating and will likely lead to the disruption of other dogmatic
assumptions, similar to what has been observed for the BBB integrity
during inflammation over the past decade. The experimental and clini-
cal evidence, associated with the powerful molecular tools, is expected
to overcome the limited availability of biological samples from pa-
tients and this is likely to encourage the search for new biomarkers
or unsuspected mechanisms, such as the microbiota [124,125]. Fur-
thermore, enormous unanswered questions remain to be addressed,
as in the case of the immunology of autism spectrum disorder [126]
which is expected to provide new data in an exponential fashion [127],
thanks to the enormous social pressure related to the growing inci-
dence of the disease, or in overlooked conditions such as myasthe-
nia gravis [128–130]. We are convinced that, despite the specialistic
view of neurological disorders, only a multidisciplinary approach to
research will provide sufficient insights to address the common key
questions on the pathogenesis and etiology of neuropsychiatric im-
mune-mediated diseases.
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